GenSight Biologics S.A.
Develops gene therapies for neurodegenerative retinal and central nervous system diseases.
SIGHT | PA
Overview
Corporate Details
- ISIN(s):
- FR0013183985 (+3 more)
- LEI:
- 549300NK4AB8OUEX1F54
- Country:
- France
- Address:
- 74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
- Sector:
- Manufacturing
Description
GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-07-04 20:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 206.1 KB | ||
| 2022-06-16 07:30 |
Inside Information / Other news releases
|
English | 125.0 KB | ||
| 2022-06-16 07:30 |
Informations privilégiées / Autres communiqués
|
French | 127.1 KB | ||
| 2022-06-01 20:00 |
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 206.1 KB | ||
| 2022-05-19 07:30 |
Informations privilégiées / Autres communiqués
|
French | 179.1 KB | ||
| 2022-05-19 07:30 |
Inside Information / Other news releases
|
English | 140.6 KB | ||
| 2022-05-04 18:13 |
Terms of availability of the preparatory documents for the GM
|
English | 201.7 KB | ||
| 2022-05-04 18:13 |
Modalités de mise à disposition des documents préparatoires à l'AG
|
French | 117.3 KB | ||
| 2022-04-29 17:45 |
Annual financial and audit reports / Terms of availability of the annual financ…
|
English | 162.4 KB | ||
| 2022-04-29 17:45 |
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 163.8 KB | ||
| 2022-04-29 13:11 |
Universal Registration Document 2021
|
English | 69.1 MB | ||
| 2022-04-29 13:11 |
Universal Registration Document 2021
|
French | 69.1 MB | ||
| 2022-04-21 07:30 |
Information financière trimestrielle / Information financière du premier trimes…
|
French | 197.3 KB | ||
| 2022-04-21 07:30 |
Quarterly financial reporting / First quarter financial report
|
English | 184.2 KB | ||
| 2022-04-14 07:30 |
Inside Information / Other news releases
|
English | 174.7 KB |
Automate Your Workflow. Get a real-time feed of all GenSight Biologics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GenSight Biologics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GenSight Biologics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-09 | N/A | Other | Other | 5,063,291 | 1,999,999.95 EUR |
| 2024-02-07 | N/A | Other | Other | 5,224,660 | 1,999,999.85 EUR |
| 2023-11-21 | N/A | Other | Other | 3,038,279 | 2,163,862.30 EUR |
Peer Companies
